natgillin/translations-raw huggingface dataset:
EXPIRY DATE EXP {MM/YYY} BATCH NUMBER Batch nr. {xxxxxx} CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Presentation of 200 mg/100 ml: 100 ml OTHER
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP {MM/LLLL} ŠTEVILKA SERIJE Serija {xxxxxx} VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT Pakiranje z 200 mg/100 ml: 100 ml DRUGI PODATKI
- The literature provided by the applicant support a dose of 200 - 400 mg twice daily in the treatment of complicated urinary tract infections and a maximum adult daily dose of 400 mg three times daily.
- literature, ki jo je predložil vlagatelj in ki govori v prid odmerku 200 do 400 mg dvakrat dnevno pri zdravljenju zapletenih okužb sečil ter največjemu odmerku pri odraslih, ki znaša 400 mg trikrat dnevno,
Ear and labyrinth disorders: Rare: tinnitus, transient hearing loss (particularly high frequencies).
Ušesne bolezni, vključno z motnjami labirinta: Redki: tinitus, prehodna izguba sluha (zlasti visokih frekvenc).
There are limited data on the use of ciprofloxacin during pregnancy.
Podatki o uporabi ciprofloksacina v nosečnosti so omejeni.
Rare: taste loss (reduced taste), paraesthesia (peripheral paralgesia), tremor (shaking), convulsions, migraine.
Redki: izguba okusa (zmanjšan čut okusa), parestezija (periferna paralgezija), tremor (tresenje), konvulzije, migrena.
In patients with a creatinine clearance in the range 31 - 60 ml/minute/1.73 m2 or a serum creatinine concentration in the range 124 - 174 µmol/l, the maximum daily intravenous dose is 800 mg.
Okvarjeno delovanje ledvic: Pri bolnikih s kreatininskim očistkom od 31 do 60 ml/min/1,73 m2 ali koncentracijo kreatinina v serumu od 124 do 174 µmol/l je največji dnevni intravenski odmerek 800 mg.
According to EUCAST the following breakpoints for aerobic bacteria have been defined for ciprofloxacin:
Po merilih odbora EUCAST so za aerobne bakterije opredelili naslednje mejne vrednosti za ciprofloksacin:
After oral administration 45% is excreted unchanged in the urine and 25% is excreted in the faeces.
Po peroralni uporabi se 45 % izloči nespremenjenega v urinu, 25 % pa v blatu.
If there is any indication of tendinitis (e.g. painful swelling) the administration of ciprofloxacin or other fluoroquinolones must immediately be discontinued, the affected extremity should not be strained and a physician must be consulted.
Če se pojavijo kakršni koli znaki tendinitisa (npr. boleča oteklina), je treba zdravljenje s ciprofloksacinom ali drugimi fluorokinoloni takoj ustaviti, prenehati je treba telesno dejavnost in se posvetovati z zdravnikom.
Side effects have been reported in 5-14% of patients receiving ciprofloxacin.
O neželenih učinkih so poročali pri 5-14 odstotkih bolnikov, ki so prejemali ciprofloksacin.
Mutagenicity of ciprofloxacin has not been indicated in mutagenicity studies.
Mutagenosti ciprofloksacina v študijah mutagenosti niso pokazali.
If such reactions occur, treatment with ciprofloxacin must be discontinued immediately and the treating physician informed.
Če se pojavijo take reakcije, je treba zdravljenje s ciprofloksacinom takoj prekiniti in obvestiti lečečega zdravnika.
• Ciprofloxacin may inhibit the excretion of methotrexate via the kidney, causing an increased methotrexate level in the blood.
• ciprofloksacin lahko zavre izločanje metotreksata skozi ledvica, zaradi česar se lahko raven metotreksata v krvi poveča;
Ciprofloxacin is effective in vitro against a large number of Gram-negative aerobic bacteria including P. aeruginosa.
Ciprofloksacin je in vitro učinkovit proti velikem številu gramnegativnih aerobnih bakterij, vključno s P. aeruginosa.
Hypersensitivity reactions and allergic reactions occurred in some cases after the first administration of ciprofloxacin.
Preobčutljivostne in alergijske reakcije so se v nekaterih primerih pojavile že po prvem odmerku ciprofloksacina.
However, since decreased clearance of diazepam, with a prolonged half-life have been reported during co-administration of ciprofloxacin and diazepam, and in very rare cases with midazolam, careful monitoring of benzodiazepine therapy is recommended.
Vendar so pri sočasni uporabi ciprofloksacina in diazepama ter v zelo redkih primerih midazolama poročali o zmanjšanem očistku in podaljšanem razpolovnem času diazepama, zato se priporoča pozorno spremljanje zdravljenja z benzodiazepinom.
Like all medicines, Ciprofloxacin Hikma can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Ciprofloxacin Hikma neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Resistance to ciprofloxacin develops in stages through genomic mutations (multiple-step type).
Rezistenca za ciprofloksacin se razvija postopno skozi genomske mutacije (po korakih).
Therefore, patients receiving methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
Zato je treba bolnike, ki prejemajo metotreksat, pri sočasnem zdravljenju s ciprofloksacinom pozorno spremljati.
You must not breast-feed your child during treatment with ciprofloxacin, due to the risk of malformation of joint cartilage and other harmful effects in the breast-fed infant.
Med zdravljenjem s ciprofloksacinom ne smete dojiti, zaradi tveganja za deformacije hrustanca v sklepih dojenčka ali druge škodljive učinke.
The following indications can be considered for treatment with Ciprofloxacin Hikma when oral therapy is not possible or not reliable: - complicated urinary tract infections - infections of the lower respiratory tract including pneumonia caused by aerobic gram-negative bacteria, in case of Streptococcus pneumoniae infections ciprofloxacin is not the substance of first choice.
Zdravilo Ciprofloxacin Hikma se lahko uporabi za naslednje indikacije, kadar peroralno zdravljenje ni mogoče ali zanesljivo: - zapletene okužbe sečil; - okužbe spodnjih dihal, vključno s pnevmonijo, ki jo povzročajo aerobne grampozitivne bakterije; pri okužbah z bakterijo Streptococcus pneumoniae, ciprofloksacin ni zdravilo prve izbire; - zapletene okužbe kože in mehkih tkiv; - osteomielitis.
Ciprofloxacin inhibits DNA-gyrase, resulting in inhibition of DNA synthesis.
Ciprofloksacin zavira DNA-girazo, kar povzroči zaviranje sinteze DNA.
• patients with a hypersensitivity to ciprofloxacin, quinoline carboxylic acid derivatives or to any of the excipients
• bolnikih, ki so preobčutljivi za ciprofloksacin, derivate kinolin-karboksilne kisline ali katero koli pomožno snov;
For the treatment of acute pulmonary infections caused by Pseudomonas aeruginosa bacteria in children and adolescents (5-17 years) with cystic fibrosis 15 mg of ciprofloxacin per kg body weight is administered twice daily or 10 mg ciprofloxacin per kg body weight is administered three times daily (maximum 1200 mg daily).
Za zdravljenje akutnih pljučnih okužb, ki jih povzroča bakterija Pseudomonas aeruginosa pri otrocih in mladostnikih (5-17 let) s cistično fibrozo, se dvakrat na dan daje 15 mg ciprofloksacina na kg telesne teže ali trikrat na dan 10 mg ciprofloksacina na kg telesne teže (največ 1200 mg na dan).
Since the risks for humans are unknown Ciprofloxacin Hikma must not be administered during pregnancy (see section 4.3).
Tveganje za človeka ni znano, zato se zdravilo Ciprofloxacin Hikma med nosečnostjo ne sme uporabljati (glejte poglavje 4.3).
Rare: photosensibility, erythema multiforme and erythema nodusum.
Redki: fotosenzitivnost, multiformni eritem in nodozni eritem.
Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.
Bolniki, ki jemljejo ciprofloksacin, morajo dobivati dovolj tekočine, poleg tega je treba preprečiti, da bi postal urin izrazito alkalen.
If these reactions recur or exacerbate during a following infusion no further infusions should be administered.
Če se te reakcije med infundiranjem pojavijo znova ali se poslabšajo, se zdravilo ne sme več infundirati;
This may increase the effect of glibenclamide (too low blood sugar level).
Lahko se okrepi učinek glibenklamida (prenizek sladkor v krvi);
Concentrations in pulmonary tissue, gynaecological tissue and prostate tissue and fluid were also significantly higher than the serum concentration.
Koncentracije v pljučnem tkivu, tkivu rodil in tkivu ter tekočini prostate so prav tako večje kot v serumu.
• theophylline (used to treat asthma), clozapine (used to treat schizophrenia), tacrine (used to treat symptoms of Alzheimer´s disease), ropinirol (used to treat Parkinson disease) and tizanidine (used to treat muscle spasms).
• teofilin (za zdravljenje astme), klozapin (za zdravljenje shizofrenije), takrin (za zdravljenje simptomov Alzheimerjeve bolezni), ropinirol (za zdravljenje Parkinsonove bolezni) in tizanidin (za zdravljenje mišičnih krčev).
If you have kidney problems you should inform your doctor.
Če imate težave z ledvicami, morate obvestiti zdravnika.
Ciprofloxacin Hikma contains 15.4 mmol (354 mg) sodium per 100 ml of solution for infusion.
Zdravilo Ciprofloxacin Hikma vsebuje 15,4 mmol (354 mg) natrija na 100 ml raztopine za infundiranje.
Staphylococcus aureus (methicillin susceptible) Streptococcus spp.
Staphylococcus aureus (dovzeten za meticilin) Streptococcus spp.
Oral administration of 20 mg/kg twice daily to children with cystic fibrosis gives an exposure that is comparable to that in adults following an oral dose of 750 mg twice daily.
Pri otrocih s cistično fibrozo je izpostavljenost po peroralnem odmerjanju 20 mg/kg dvakrat na dan primerljiva z izpostavljenostjo pri odraslih po peroralnem odmerku 750 mg dvakrat na dan.
Commonly susceptible species Gram-negative aerobe species Citrobacter spp.
Gramnegativne aerobne vrste Citrobacter spp.
On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.
Med sočasno uporabo ciprofloksacina in kofeina ali pentoksifilina (okspentifilina) so poročali o povečanih koncentracijah ksantinskih derivatov.
The solution for infusion should be administered over an infusion period of 60 minutes.
Infundiranje raztopine za infundiranje mora trajati 60 minut.
In that case, the ciprofloxacin treatment must be discontinued, and medical treatment for shock should be given.
V tem primeru je treba zdravljenje s ciprofloksacinom prekiniti in zdraviti šok.
You must not be given Ciprofloxacin Hikma during pregnancy.
Zdravila Ciprofloxacin Hikma vam med nosečnostjo ne smejo dati.
Inherently resistant organisms Gram-positive aerobes
Pseudomonas aeruginosa Inherentno rezistentni organizmi Grampozitivni aerobi:
* MRSA are very likely to be resistant to ciprofloxacin and ciprofloxacin should not be used to treat presumed or known MRSA infections unless the organism is known to be susceptible.
* Pri bakteriji Staphylococcus aureus, rezistentni na meticilin (MRSA) je rezistenca za ciprofloksacin zelo verjetna, zato se ciprofloksacin ne sme uporabljati za zdravljenje okužb, pri katerih MRSA domnevni ali znani povzročitelj, razen kadar je znano, da je organizem dovzeten.
Probenecid inhibits the renal excretion of ciprofloxacin resulting in an increase in the plasma concentration of ciprofloxacin.
Probenecid zavira izločanje ciprofloksacina skozi ledvice, kar povzroči povečanje koncentracije ciprofloksacina v plazmi.
It is recommended that opiate premedicants, (e.g. papaveretum) or opiate premedicants used with anticholinergic premedicants, (e.g. atropine or hyoscine) are not used concomitantly with ciprofloxacin, as the serum levels of ciprofloxacin are reduced.
Priporočeno je, da se opiatna premedikacija (npr. papaveretum) ali opiatna premedikacija, ki se uporablja z antiholinergično premedikacijo (npr. atropin ali hioscin), ne uporablja sočasno s ciprofloksacinom, ker se ravni ciprofloksacina znižajo.
As with other fluoroquinolones, specific undesirable effects with regard to the central nervous system must be taken into account when using Ciprofloxacin Hikma.
Kot pri drugih fluorokinolonih je treba tudi pri uporabi zdravila Ciprofloxacin Hikma upoštevati možnost pojava določenih neželenih učinkov na osrednje živčevje.
Symptoms of overdose may include dizziness, tremor, headaches, tiredness, seizures, hallucinations, confusion, gastrointestinal upset, liver and kidney abnormalities, crystalluria, haematuria.
Simptomi prevelikega odmerjanja so lahko omotica, tremor, glavoboli, utrujenost, epileptični napadi, halucinacije, konfuznost, prebavne težave, abnormalnosti jeter in ledvic, kristalurija in hematurija.
The duration of treatment with Ciprofloxacin Hikma is based on the severity of the infection, the effect of the treatment and the sensitivity of the pathogen(s).
Trajanje zdravljenja z zdravilom Ciprofloxacin Hikma je odvisno od stopnje okužbe, učinka zdravljenja in občutljivosti povzročitelja (povzročiteljev).
Very rare: vasculitis (petechiae, hemorrhagic bullae, papules, crust formation).
Zelo redki: vaskulitis (petehije, hemoragične bule, papule, tvorba krast).
• Pre-medicants (used before anaesthesia induction): it is recommended that opiate pre-medicants, (e.g. papaveretum) or opiate pre-medicants used with anticholinergic pre-medicants, (e.g. atropine or hyoscine) are not used concomitantly with ciprofloxacin, as the serum levels of ciprofloxacin are reduced.
• premedikacije (zdravila, ki se uporabljajo pred anestezijo): priporočeno je, da se opiatna premedikacija (npr. papaveretum) ali opiatna premedikacija, ki se uporablja z antiholinergično premedikacijo (npr. atropin ali hioscin), ne uporablja sočasno s ciprofloksacinom, ker se ravni ciprofloksacina znižajo.
The ciprofloxacin concentration in blister fluid, lymph, nasal secretion, peritoneal fluid, saliva and fatty tissue is approximately half of the serum concentration.
Koncentracija ciprofloksacina v tekočini mehurjev, limfi, izcedku iz nosu, peritonealni tekočini, slini in maščobnem tkivu je približno za polovico manjša kot v serumu.
• phenytoin (used to treat epilepsy).
• fenitoin (za zdravljenje epilepsije).
Transferable plasmid-mediated quinolone resistance associated with qnr has been detected in quinolone-resistant clinical strains of E.coli and Klebsiella spp.
Prenosljivo rezistenco za kinolone, povezano z genom qnr, ki se prenaša s plazmidi, so odkrili pri sevih bakterij E.coli in Klebsiella spp, rezistentnih na kinolone.
The blood level of these medicines can be increased.
Raven teh zdravil v krvi se lahko poveča;
Each vial with 100 ml contains 200 mg ciprofloxacin.
Vsaka 100-mililitrska viala vsebuje 200 mg ciprofloksacina.
Very rare: tendinitis (in particular of the Achilles tendon), partial or total tendon ruptures (in particular of the Achilles tendon), worsening of the symptoms of myasthenia, muscular pains, inflammation of tendon sheaths (tenosynovitis).
Zelo redki: tendinitis (zlasti ahilove kite), delna ali celotna ruptura kit (zlasti ahilove kite), slabšanje simptomov miastenije, bolečine v mišicah, vnetje ovojnic kit (tendosinovitis).
Ciprofloxacin Hikma is contraindicated in:
Zdravilo Ciprofloxacin Hikma je kontraindicirano pri:
Lactic acid (E270), sodium chloride, hydrochloric acid (E507) and water for injection.
Mlečna kislina (E 270), natrijev klorid, klorovodikova kislina (E 507) in voda za injekcije.
Uncommon: increase of blood creatinine levels, increased blood urea; abnormal liver function test results (increased SGOT and SGPT), bilirubinemia and increased alkaline phosphatase.
Občasni: zvišanje ravni kreatinina v krvi, zvišanje uree v krvi, nenormalni rezultati jetrnih preiskav (zvišana AST in ALT), bilirubinemija in zvišana alkalna fosfataza.
with cystic fibrosis:
let, s cistično fibrozo;
The total body clearance of ciprofloxacin is independent of the dose and remains unchanged in case of multiple administrations.
Skupni očistek ciprofloksacina je odvisen od odmerka in pri večkratni uporabi ostaja nespremenjen.
Type I, clear glass vial, fitted with a chlorobutyl rubber stopper and aluminium flip-off caps.
Prozorna viala iz stekla vrste I z gumijastim zamaškom iz klorobutila in z aluminijastim pokrovom "flip-off".
Coagulase-negative Staphylococcus Enterococcous faecalis
Staphylococcus, negativen na koagulazo Enterococcous faecalis
No accumulation occurs on repeated administration (twice daily).
Ob ponavljajoči se uporabi (dvakrat na dan) ne prihaja do kopičenja.
It affects the lungs, sweat glands and the digestive system causing chronic respiratory and digestive problems.
Vpliva na pljuča, znojnice in prebavila, povzroča pa težave z dihanjem in prebavo.
In patients with epilepsy or other lesions of the central nervous system (e.g. reduced convulsion threshold, a history of epileptic seizures, diminished cerebral blood flow, changes in brain structure or stroke), ciprofloxacin is only to be used after carefully weighing the benefits against the risk, because the possibility of central nervous side effects puts these patients at increased risk.
Pri bolnikih z epilepsijo ali drugimi motnjami osrednjega živčevja (npr. znižanim pragom za konvulzije, anamnezo epileptičnih napadov, zmanjšanim možganskim krvnim pretokom, spremembami v strukturi možganov ali možgansko kapjo) se lahko ciprofloksacin uporablja le po temeljiti oceni tveganja in koristi.
In addition, other amendments to the Summary of Product Characteristics, labelling and package leaflet not in relation with the outcome of the referral procedure were included in accordance with the Guideline on SPC, excipient guideline and the latest Quality Review of Documents templates.
Dodatno so bila v skladu s smernicami o SPC, smernicami o pomožnih snoveh in zadnjimi predlogami za pregledovanje kakovosti dokumentov, vključena tudi druga dopolnila Povzetka glavnih značilnosti zdravila, označevanja in Navodila za uporabo, ki niso povezana z rezultatom napotitvenega postopka.
• In children and growing adolescents except for the treatment of acute lower respiratory tract infections caused by Pseudomonas aeruginosa bacteria in children and adolescents aged
• pri otrocih in odraščajočih mladostnikih, razen za zdravljenje akutnih okužb; spodnjih dihal, ki jih povzroča bakterija Pseudomonas aeruginosa pri otrocih in mladostnikih, starih od 5 do 17
Respiratory, thoracic and mediastinal disorders: Rare: dyspnoea, laryngeal oedema.
Bolezni dihal, prsnega koša in mediastinalnega prostora: Redki: dispneja, laringealni edem.
In case of any symptom indicating an exacerbation of myastenia gravis, you should therefore consult your doctor.
Če se pojavijo simptomi, ki kažejo na poslabšanje miastenije gravis, se morate posvetovati z zdravnikom;
Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma concentrations of mexiletine.
Meksiletin Sočasna uporaba ciprofloksacina in meksiletina lahko poveča koncentracijo meksiletina v plazmi.
Ciprofloxacin Hikma can also be used for the treatment of acute lower respiratory tract infections caused by Pseudomonas aeruginosa bacteria in children and adolescents aged 5-17 years with cystic fibrosis (also called mucoviscidosis), a hereditary disease of specific glands.
Zdravilo Ciprofloxacin Hikma se lahko uporablja tudi za zdravljenje akutnih okužb spodnjih dihal, ki jih povzroča bakterija Pseudomonas aeruginosa pri otrocih in mladostnikih, starih od 5 do 17 let, s cistično fibrozo (imenovano tudi mukoviscidoza), dedno boleznijo določenih žlez.
Ciprofloxacin is a quinolone effective in vitro against a large number of Gram-negative aerobic bacteria as well as against some Gram-positive organisms.
Zdravilo Ciprofloxacin je kinolon, ki in vitro učinkuje proti velikemu številu različnih gramnegativnih aerobnih bakterij kot tudi proti nekaterim grampozitivnim organizmom.
Klebsiella oxytoca
Klebsiella pneumoniae Klebsiella oxytoca
administration 62% is excreted unchanged in the urine and 15% is excreted in the faeces.
Po intravenski uporabi se 62 % izloči nespremenjenega v urinu, 15 % pa v blatu.
Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose.
Bolnike, ki te snovi jemljejo sočasno s ciprofloksacinom, je zato treba nadzorovati zaradi morebitnih znakov prevelikega odmerjanja.
Because ciprofloxacin has some activity against Mycobacterium tuberculosis, false-negative cultures may occur when the specimens are obtained during ciprofloxacin treatment.
Ciprofloksacin nekoliko učinkuje proti bakteriji Mycobacterium tuberculosis, zato se, kadar vzorce odvzemamo med zdravljenjem s ciprofloksacinom, lahko pojavijo lažno negativne kulture.
If you suffer from this disease, you should consult your doctor.
Če imate to bolezen, se morate posvetovati z zdravnikom;
Rare: acute renal failure, impaired renal function, vaginal moniliasis, haematuria, crystalluria, interstitial nephritis.
Redki: akutna ledvična odpoved, okvara delovanja ledvic, vaginalna kandidoza, hematurija, kristalurija, intersticijski nefritis.
Clear, colourless to slightly yellow solution pH of the solution: 3.9 - 4.5
FARMACEVTSKA OBLIKA Raztopina za infundiranje Bistra, brezbarvna do rahlo rumena raztopina pH raztopine: 3,9-4,5
• pregnancy and lactation
• nosečnosti in dojenju;
Common: nausea, diarrhoea.
Pogosti: navzeja, diareja.
Dosage as follows:
Odmerjanje poteka na naslednji način:
STATEMENT OF ACTIVE SUBSTANCE(S) 1 ml solution for infusion contains : Ciprofloxacin lactate equivalent to 2 mg ciprofloxacin.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 1 ml raztopine za infundiranje vsebuje: ciprofloksacinlaktat, ki ustreza 2 mg ciprofloksacina.
Very rare: parosmia (impaired smell), anosmia (usually reversible after interruption), grand mal convulsion, abnormal (unstable) gait, intracranial hypertension, ataxia, hyperesthesia, hypertonia.
Zelo redki: parozmija (popačenje čuta za voh), anozmija (ponavadi reverzibilna po prekinitvi zdravljenja), generaliziran epileptični napad, nenormalna (nestabilna) hoja, intrakranialna hipertenzija, ataksija, hiperestezija, hipertonija.
General disorders and administration site conditions:
Splošne težave in spremembe na mestu uporabe:
Uncommon: (thrombo) phlebitis.
Občasni: (trombo)flebitis.
• probenecid (used to treat gout).
• probenecid (za zdravljenje protina).
Most frequent adverse effects involve the gastro-intestinal tract and the central nervous system.
Najpogostejši neželeni učinki zdravila prizadenejo prebavila in osrednje živčevje.
The adult dosage is 200 - 400 mg ciprofloxacin twice daily.
Odmerek za odrasle je 200-400 mg ciprofloksacina dvakrat na dan.
Rare: icterus, cholestatic icterus, liver cell necrosis.
Redki: ikterus, holestatski ikterus, nekroza jetrnih celic.
Antiperistaltics are contraindicated.
Uporaba zdravil, ki zavirajo peristaltiko, je kontraindicirana.
Uncommon: vomiting, dyspepsia, flatulence, anorexia, abdominal pain.
Občasni: bruhanje, dispepsija, flatulenca, anoreksija, bolečine v trebuhu.
Rare: leukopenia (granulocytopenia), anaemia, leukocytosis, altered prothrombin values, thrombocytopenia, thrombocytemia (thrombocytosis).
Redki: levkopenija (granulocitopenija), anemija, levkocitoza, spremenjene vrednosti protrombina, trombocitopenija, trombocitemija (trombocitoza).
- Enterobacteriaceae: ≤ 0.5 µg/ml for susceptible, > 1 µg/ml for resistant; - Pseudomonas spp.
- Enterobacteriaceae: ≤ 0,5 µg/ml za dovzetne, > 1 µg/ml za rezistentne; - Pseudomonas spp.
• glucose-6-phosphate dehydrogenase defect (hereditary disease of the red blood cells based on a defect in an enzyme).
• okvara glukoza-6-fosfat-dehidrogenaze (dedna bolezen eritrocitov, katere vzrok je okvara encima).
Ciprofloxacin Hikma is compatible with physiological sodium chloride solution, Ringer's solution, Ringer's lactate solution, 50 mg/ml (5 %) or 100 mg/ml (10 %) glucose solution and 50 mg/ml (5 %) glucose solution with 2.25 mg/ml (0.225 %) or 4.5 mg/ml (0.45 %) sodium chloride solution and 10% fructose solution.
Zdravilo Ciprofloxacin Hikma je združljivo s fiziološko raztopino natrijevega klorida, Ringerjevo raztopino, raztopino Ringerjevega laktata, 5-odstotno (50 mg/ml) ali 10-odstotno (100 mg/ml) raztopino glukoze in 5-odstotno (50 mg/ml) raztopino glukoze z 0,225-odstotno (2,25 mg/ml) ali 0,45-odstotno (4,5 mg/ml) raztopino natrijevega klorida in 10-odstotno raztopino fruktoze.